z-logo
Premium
Role of the Copper( II ) Complex Cu[15]pyN 5 in Intracellular ROS and Breast Cancer Cell Motility and Invasion
Author(s) -
Fernandes Ana S.,
Flórido Ana,
Saraiva Nuno,
Cerqueira Sara,
Ramalhete Sérgio,
Cipriano Madalena,
Cabral Maria Fátima,
Miranda Joana P.,
Castro Matilde,
Costa Judite,
Oliveira Nuno G.
Publication year - 2015
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12521
Subject(s) - intracellular , doxorubicin , motility , cancer research , breast cancer , cancer cell , cell migration , apoptosis , mcf 7 , cell , chemistry , cell growth , cell culture , cancer , chemotherapy , biology , microbiology and biotechnology , medicine , biochemistry , human breast , genetics
Multiple mechanisms related to metastases undergo redox regulation. Cu[15]pyN 5 is a redox‐active copper( II ) complex previously studied as a chemotherapy sensitizer in mammary cells. The effects of a cotreatment with Cu[15]pyN 5 and doxorubicin (dox) were evaluated in two human breast cancer cell lines: MCF 7 (low aggressiveness) and MDA ‐ MB ‐231 (highly aggressive). Cu[15]pyN 5 decreased MCF 7‐directed cell migration. In addition, a cotreatment with dox and Cu[15]pyN 5 reduced the proteolytic invasion of MDA ‐ MB ‐231 cells. Cell detachment was not affected by exposure to these agents. Cu[15]pyN 5 and dox significantly increased intracellular ROS in both cell lines. This increase could be at least partially due to H 2 O 2 accumulation. The combination of Cu[15]pyN 5 with dox may be beneficial in breast cancer treatment as it could help reduce cancer cell migration and invasion. Moreover, the ligand [15]pyN 5 has a high affinity for copper( II ) and displays potential anti‐angiogenic properties. Overall, we present a potential drug that might arrest the progression of breast cancer by different and complementary mechanisms.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here